secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2026-06-01T11:55:09+00:00
Accession:  0001193125-26-249763
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK
--------------------------------------------------------------------------------

- Mean IgA reduction ~70% from baseline, sustained at 12 weeks with single 700 mg dose; steady-state simulation supports Q12W dosing.
- JADE101 estimated 379-fold more potent than sibeprenlimab and 26-fold more potent than povetacicept in IgA-lowering.
- Favorable safety: no serious AEs, no discontinuations, no hypogammaglobulinemia; most common AEs were headache (25%), URTI (21.9%).
- Half-life at steady state ~8.7x longer than povetacicept and ~2.6x longer than sibeprenlimab, supporting convenient dosing (4 injections/year).
- Phase 2 JUNIPER trial ongoing; registrational Phase 3 planned for H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526249763/0001193125-26-249763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526249763/d124589d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-249763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer